Cytoplasmic TRADD confers a worse prognosis in glioblastoma

Neoplasia (United States)

Volumn 15, Issue 8, 2013, Pages 888-897

  Chakraborty, Sharmistha ^a   Li, Li ^a   Tang, Hao ^b   Xie, Yang ^b   Puliyappadamba, Vineshkumar Thidil ^a   Raisanen, Jack ^a   Burma, Sandeep ^a   Boothman, David A ^c   Cochran, Brent ^d   Wu, Julian ^d   Habib, Amyn A ^a,c,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LUCIFERASE; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 84881060176     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13608     Document Type: Article

References (48)

1. Hsu H, Xiong J, and Goeddel DV (1995). The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81, 495-504.
2. Pobezinskaya YL and Liu Z (2012). The role of TRADD in death receptor signaling. Cell Cycle 11, 871-876.
3. Aggarwal BB (2003). Signalling pathways of the TNF superfamily: a doubleedged sword. Nat Rev Immunol 3, 745-756.
4. Chen NJ, Chio II, Lin WJ, Duncan G, Chau H, Katz D, Huang HL, Pike KA, Hao Z., Su YW, et al. (2008). Beyond tumor necrosis factor receptor: TRADD signaling in toll-like receptors. Proc Natl Acad Sci USA 105, 12429-12434.
5. Hsu H, Shu HB, Pan MG, and Goeddel DV (1996). TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84, 299-308.
6. Micheau O and Tschopp J (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181-190.
7. Morgan M, Thorburn J, Pandolfi PP, and Thorburn A (2002). Nuclear and cytoplasmic shuttling of TRADD induces apoptosis via different mechanisms. J Cell Biol 157, 975-984.
8. Chio II, Sasaki M, Ghazarian D, Moreno J, Done S, Ueda T, Inoue S, Chang YL, Chen N. J, and Mak TW (2012). TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation. Nat Cell Biol 14, 625-633.
9. Wesemann DR, Qin H, Kokorina N, and Benveniste EN (2004). TRADD interacts with STAT1-α and influences interferon-γ signaling. Nat Immunol 5, 199-207.
10. Scheuerpflug CG, Lichter P, Debatin KM, and Mincheva A (2001). Assignment of TRADD to human chromosome band 16q22 by in situ hybridization. Cytogenet Cell Genet 92, 347-348.
11. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, and Davis FG (1999). Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1, 14-25.
12. Reardon DA and Wen PY (2006). Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11, 152-164.
13. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro J. M, Colman H, Soroceanu L, et al. (2006). Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173.
14. Mischel PS, Cloughesy TF, and Nelson SF (2004). DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 5, 782-792.
15. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne S. L, Doetsch F, Colman H, et al. (2010). The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318-325.
16. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110.
17. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, and Holland E (2009). Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4, e7752.
18. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H., Siu IM, Gallia GL, et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812.
19. Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
20. Karin M, Cao Y, Greten FR, and Li ZW (2002). NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2, 301-310.
21. Pacifico F and Leonardi A (2006). NF-κB in solid tumors. Biochem Pharmacol 72, 1142-1152.
22. Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, and Liu J (2013). Interleukin-1β promotes ovarian tumorigenesis through a p53/ NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia 15, 409-420.
23. Jain G, Voogdt C, Tobias A, Spindler KD, Moller P, Cronauer MV, and Marienfeld R. B (2012). IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. Neoplasia 14, 178-189.
24. Thomasova D, Mulay SR, Bruns H, and Anders HJ (2012). p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 14, 1097-1101.
25. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, Ramnarain DB, Xiao G, Saha D, Boothman DA, et al. (2009). The receptor interacting protein 1 inhibits p53 induction through NF-κB activation and confers a worse prognosis in glioblastoma. Cancer Res 69, 2809-2816.
26. Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, et al. (2011). NFKBIA deletion in glioblastomas. N Engl J Med 364, 627-637.
27. Sun L and Carpenter G (1998). Epidermal growth factor activation of NF-κB is mediated through IκBα degradation and intracellular free calcium. Oncogene 16, 2095-2102.
28. Habib AA, Chatterjee S, Park SK, Ratan RR, Lefebvre S, and Vartanian T (2001). The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-κB (NF-κB)-inducing kinase to activate NF-κB. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem 276, 8865-8874.
29. Biswas DK, Cruz AP, Gansberger E, and Pardee AB (2000). Epidermal growth factor-induced nuclear factor κB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97, 8542-8547.
30. Hatanpaa KJ, Burma S, Zhao D, and Habib AA (2010). Epidermal growth factor receptor (EGFR) in glioma: signal transduction, neuropathology, imaging and radioresistance. Neoplasia 12, 675-684.
31. Eyler CE and Rich JN (2012). Looking in the miR-ror: TGF-β-mediated activation of NF-κB in glioma. J Clin Invest 122, 3473-3475.
32. Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, Lathia JD, Macswords J., Lee J, McLendon RE, et al. (2010). Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol 8, e1000319.
33. Park S, Zhao D, Hatanpaa KJ, Mickey BE, Saha D, Boothman DA, Story MD, Wong E. T, Burma S, Georgescu MM, et al. (2009). RIP1 activates PI3K-Akt via a dual mechanism involving NF-κB-mediated inhibition of the mTOR-S6KIRS1 negative feedback loop and down-regulation of PTEN. Cancer Res 69, 4107-4111.
34. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano M. D, and Dirks PB (2004). Identification of human brain tumour initiating cells. Nature 432, 396-401.
35. Collett D (2003). Modelling Survival Data in Medical Research. Chapman & Hall/CRC, New York, NY.
36. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403.
37. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Lafarga M, Berciano MT, Aldaz B., Grande L, Casafont I, Segura V, Robles EF, et al. (2011). Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo. Oncogene 30, 3537-3548.
38. Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J, Hulit J, Sakamaki T, Fu M, Ben-Ze'ev A, et al. (2003). IKKα regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell 14, 585-599.
39. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, and Karin M (2001). IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107, 763-775.
40. Chien Y, Kim S, Bumeister R, Loo YM, Kwon SW, Johnson CL, Balakireva MG, Romeo Y, Kopelovich L, Gale M Jr, et al. (2006). RalB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127, 157-170.
41. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N., Beug H, and Wirth T (2004). NF-κB is essential for epithelialmesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114, 569-581.
42. Perkins ND (2007). Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 8, 49-62.
43. Schneider G, Saur D, Siveke JT, Fritsch R, Greten FR, and Schmid RM (2006). IKKα controls p52/RelB at the skp2 gene promoter to regulate G1-to S-phase progression. EMBO J 25, 3801-3812.
44. Aggarwal BB (2004). Nuclear factor-κB: the enemy within. Cancer Cell 6, 203-208.
45. Pahl HL (1999). Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853-6866.
46. Kirillova I, Chaisson M, and Fausto N (1999). Tumor necrosis factor induces DNA replication in hepatic cells through nuclear factor κB activation. Cell Growth Differ 10, 819-828.
47. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, and Strauss M (1999). NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19, 2690-2698.
48. Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH, and Sonenshein G. E (2000). The RelA NF-κB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 19, 5498-5506.